Therapy-enhancing glucan

• US 9,211,304 B2
• Filed: 02/06/2013
• Issued: 12/15/2015
• Est. Priority Date: 07/16/2003
• Status: Expired due to Fees

• Current Assignee: Biotec BetaGlucans AS (Lallemand Inc.), Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Biotec Pharmacon ASA, Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Cheung, Nai-Kong V., Engstad, Rolf Einar
• Primary Examiner(s): Olson, Eric
• Application Number:
  US13/760,307
• Publication Number:
  US 20130183295A1
• Time in Patent Office: 1,042 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2039/55583 Polysaccharides
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/716 Glucans
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08B 37/0024 beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Abstract

This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Claims

1. A method of treating cancer in a subject, comprising administering to said subject a soluble β

-glucan in an amount effective to treat said cancer, wherein said glucan is derived from yeast and comprises a β

-1,3 backbone with branches attached to the backbone via β

-1,6 linkages, wherein the glucose units in said branches are β

-1,3 linked, and said cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin'"'"'s lymphoma, breast cancer, non-small cell lung cancer, colorectal cancer, Epstein-Barr related lymphoma, Hodgkin'"'"'s lymphoma, and epidermoid carcinoma.

2. The method of claim 1, wherein said glucan has a molecular weight of 10-350 kDa.

3. The method of claim 1, wherein said glucan is administered orally or intravenously.

4. The method of claim 1, wherein said glucan is administered at about 25 mg/kg/day.

5. The method of claim 1, further comprising administering a complement-activating antibody.

6. The method of claim 5, wherein said antibody is a monoclonal antibody.

7. The method of claim 5, wherein said antibody is administered simultaneously or sequentially with said glucan.

8. The method of claim 5, wherein said antibody is selected from the group consisting of cetuximab, M195, Dacluzimab, R24, Herceptin, Rituximab, 528, IgG, IgM, IgA, C225, Epratuzumab and 3F8.

9. The method of claim 5, wherein said antibody is cetuximab for treating non-small cell lung cancer.

10. The method of claim 5, wherein said antibody is cetuximab for treating colorectal cancer.

11. The method of claim 5, wherein said antibody is rituximab for treating non-Hodgkin'"'"'s lymphoma.

12. The method of claim 1, further comprising administering a chemotherapeutic agent.

13. The method of claim 12, wherein said chemotherapeutic agent is carboplatin.

14. The method of claim 12, wherein said chemotherapeutic agent is irinotecan.

15. The method of claim 12, wherein said chemotherapeutic agent is paclitaxel.

16. The method of claim 12, wherein said glucan has a molecular weight of 10-350 kDa.

17. The method of claim 12, wherein said glucan is administered orally or intravenously.

18. The method of claim 12, wherein said glucan is administered at about 25 mg/kg/day.

19. The method of claim 12, wherein said chemotherapeutic agent is administered simultaneously or sequentially with said glucan.

20. The method of claim 12, wherein the cancer is non-small cell lung cancer.